Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485601 | Vaccine | 2018 | 9 Pages |
Abstract
Thus we tested the relevance of this finding in vivo on the generation of a tumour-specific memory immune response, in the TRAMP-C2 mouse prostate carcinoma transplantable model. TRAMP-C2 tumour cells treated at 56â¯Â°C were able not only to activate DCs in vitro but also to trigger a tumour-specific CTL-dependent immune response in vivo. Prophylactic vaccination with 56â¯Â°C-treated TRAMP-C2 tumour cells alone provided protection against TRAMP-C2 tumour growth in vivo, whilst in the therapeutic regimen, control of tumour growth was achieved combining immunization with adjuvant chemotherapy.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Francesco De Sanctis, Sara Sandri, Matteo Martini, Marta Mazzocco, Alessandra Fiore, Rosalinda Trovato, Stefano Garetto, Davide Brusa, Stefano Ugel, Silvia Sartoris,